Posted Sep. 30, 2011 at 9:54 a.m.
Chelsea
Research Triangle Park, N.C. — Chelsea Therapeutics filed the new drug application for Northera on Wednesday. Chelsea already has orphan drug status on Northera, its lead drug candidate. In its NDA filing, the company also requested Northera receive priority review, which could lead to an FDA decision on the drug as soon as the first quarter of next year....Copyright 2013 MedCity. All rights reserved.
Charlotte firm's drug to treat Parkinson's advances
Post a comment
Print this blog postE-mail blog post
Share
Chelsea
Research Triangle Park, N.C. — Chelsea Therapeutics filed the new drug application for Northera on Wednesday. Chelsea already has orphan drug status on Northera, its lead drug candidate. In its NDA filing, the company also requested Northera receive priority review, which could lead to an FDA decision on the drug as soon as the first quarter of next year....Copyright 2013 MedCity. All rights reserved.
Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows